Jeremy Graff serves as the Senior Vice President and Global Head of the Rare Disease Franchise at Biogen, where he plays a pivotal role in advancing innovative therapies for conditions such as Spinal Muscular Atrophy (SMA), Amyotrophic Lateral Sclerosis (ALS), and Friedreich's Ataxia. With a...
Jeremy Graff serves as the Senior Vice President and Global Head of the Rare Disease Franchise at Biogen, where he plays a pivotal role in advancing innovative therapies for conditions such as Spinal Muscular Atrophy (SMA), Amyotrophic Lateral Sclerosis (ALS), and Friedreich's Ataxia. With a robust background in the biopharmaceutical industry, Jeremy has successfully led the development and commercialization of blockbuster medicines, leveraging his deep expertise in biologics and orphan diseases. His leadership is instrumental in overseeing a diverse portfolio that includes established products like SPINRAZA and QALSODY, as well as investigational assets such as BIIB105 and BIIB115.
Jeremy's strategic vision has driven significant business development initiatives, including the acquisition of Reata Pharmaceuticals, which enhances Biogen's capabilities in rare disease treatment. His adeptness in negotiating licensing agreements with key players such as Alcyone Therapeutics and Ionis Pharmaceuticals underscores his proficiency in market access and product life-cycle management. By fostering cross-functional collaboration and utilizing market research insights, Jeremy ensures that his teams are well-equipped to navigate the complexities of commercialization in a rapidly evolving landscape.
His comprehensive skill set encompasses immunology, sales management, and digital advertising, enabling him to craft compelling branding strategies that resonate with healthcare providers and patients alike. As a P&L leader, Jeremy is committed to delivering value-driven solutions that not only meet the needs of patients with rare diseases but also drive sustainable growth for Biogen. His dedication to innovation and excellence positions him as a key figure in the biopharmaceutical sector, making a lasting impact on the lives of those affected by rare conditions.
